John P Longenecker PHD
Insider
First SEC filing: Feb. 2, 2011 · Latest: Feb. 2, 2011
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 3, 2022 | PCRX | M | 7,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| March 3, 2022 | PCRX | S | 7,000 | $71.74 | $502,180 | 18,823 Direct | -27.11% | Disposed | -64.9% (price as of 2026-10-02) |
| March 3, 2022 | PCRX | M | 7,000 | $10.81 | $75,670 | 25,823 Direct | +37.19% | Acquired | 133.2% (price as of 2026-10-02) |
| June 9, 2021 | PCRX | A | 1,066 | · | · | 18,823 Direct | +6.00% | Acquired | (price as of 2026-10-02) |
| June 9, 2021 | PCRX | A | 7,626 | · | · | 7,626 Direct | · | Acquired | (price as of 2026-10-02) |
| March 1, 2021 | PCRX | M | 5,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| March 1, 2021 | PCRX | S | 5,000 | $72.26 | $361,300 | 17,757 Direct | -21.97% | Disposed | -65.1% (price as of 2026-10-02) |
| March 1, 2021 | PCRX | M | 5,000 | $13.98 | $69,900 | 22,757 Direct | +28.16% | Acquired | 80.3% (price as of 2026-10-02) |
| June 9, 2020 | PCRX | A | 8,027 | · | · | 8,027 Direct | · | Acquired | (price as of 2026-10-02) |
| June 9, 2020 | PCRX | A | 1,260 | · | · | 17,757 Direct | +7.64% | Acquired | (price as of 2026-10-02) |
| March 12, 2020 | PCRX | M | 3,736 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| March 12, 2020 | PCRX | M | 3,736 | $1.61 | $6,015 | 16,497 Direct | +29.28% | Acquired | 1465.8% (price as of 2026-10-02) |
| Dec. 2, 2019 | PCRX | M | 3,128 | · | · | 3,736 Direct | -45.57% | Disposed | (price as of 2026-10-02) |
| Dec. 2, 2019 | PCRX | M | 872 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| Dec. 2, 2019 | PCRX | S | 1,300 | $46.13 | $59,969 | 12,761 Direct | -9.25% | Disposed | -45.4% (price as of 2026-10-02) |
| Dec. 2, 2019 | PCRX | M | 3,128 | $1.61 | $5,036 | 14,061 Direct | +28.61% | Acquired | 1465.8% (price as of 2026-10-02) |
| Dec. 2, 2019 | PCRX | M | 872 | $1.61 | $1,404 | 10,933 Direct | +8.67% | Acquired | 1465.8% (price as of 2026-10-02) |
| June 5, 2019 | PCRX | A | 8,437 | · | · | 8,437 Direct | · | Acquired | (price as of 2026-10-02) |
| June 5, 2019 | PCRX | A | 4,134 | · | · | 10,061 Direct | +69.75% | Acquired | (price as of 2026-10-02) |
| Aug. 10, 2018 | RNTX | P | 10,000 | $2.45 | $24,500 | 10,000 Direct | · | Acquired | -98.4% (price as of 2026-10-02) |
| June 13, 2018 | PCRX | A | 4,693 | · | · | 4,693 Direct | · | Acquired | (price as of 2026-10-02) |
| June 13, 2018 | PCRX | A | 782 | · | · | 5,927 Direct | +15.20% | Acquired | (price as of 2026-10-02) |
| May 15, 2018 | RNTX | A | 30,000 | · | · | 30,000 Direct | · | Acquired | (price as of 2026-10-02) |
| June 14, 2017 | PCRX | A | 2,714 | · | · | 2,714 Direct | · | Acquired | (price as of 2026-10-02) |
| June 14, 2017 | PCRX | A | 1,357 | · | · | 5,145 Direct | +35.82% | Acquired | (price as of 2026-10-02) |
| June 15, 2016 | PCRX | A | 2,975 | · | · | 2,975 Direct | · | Acquired | (price as of 2026-10-02) |
| June 15, 2016 | PCRX | A | 1,488 | · | · | 3,788 Direct | +64.70% | Acquired | (price as of 2026-10-02) |
| Jan. 12, 2016 | PCRX | P | 300 | $66.55 | $19,965 | 2,300 Direct | +15.00% | Acquired | -62.1% (price as of 2026-10-02) |
| June 3, 2015 | PCRX | A | 4,000 | · | · | 4,000 Direct | · | Acquired | (price as of 2026-10-02) |
| June 3, 2015 | PCRX | A | 2,000 | · | · | 2,000 Direct | · | Acquired | (price as of 2026-10-02) |
| March 12, 2015 | PCRX | M | 3,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| March 12, 2015 | PCRX | S 10b5-1 | 3,000 | $95.28 | $285,840 | 0 Direct | -100.00% | Disposed | -73.5% (price as of 2026-10-02) |
| March 12, 2015 | PCRX | M | 3,000 | $29.90 | $89,700 | 3,000 Direct | · | Acquired | -15.7% (price as of 2026-10-02) |
| Dec. 29, 2014 | PCRX | M | 1,000 | · | · | 3,000 Direct | -25.00% | Disposed | (price as of 2026-10-02) |
| Dec. 29, 2014 | PCRX | S 10b5-1 | 1,000 | $93.32 | $93,320 | 0 Direct | -100.00% | Disposed | -73.0% (price as of 2026-10-02) |
| Dec. 29, 2014 | PCRX | M | 1,000 | $29.90 | $29,900 | 1,000 Direct | · | Acquired | -15.7% (price as of 2026-10-02) |
| Sept. 29, 2014 | PCRX | M | 1,000 | · | · | 4,000 Direct | -20.00% | Disposed | (price as of 2026-10-02) |
| Sept. 29, 2014 | PCRX | S 10b5-1 | 1,000 | $96.40 | $96,400 | 0 Direct | -100.00% | Disposed | -73.8% (price as of 2026-10-02) |
| Sept. 29, 2014 | PCRX | M | 1,000 | $29.90 | $29,900 | 1,000 Direct | · | Acquired | -15.7% (price as of 2026-10-02) |
| June 30, 2014 | PCRX | M | 1,000 | · | · | 5,000 Direct | -16.67% | Disposed | (price as of 2026-10-02) |
| June 30, 2014 | PCRX | S 10b5-1 | 1,000 | $91.60 | $91,600 | 0 Direct | -100.00% | Disposed | -72.5% (price as of 2026-10-02) |
| June 30, 2014 | PCRX | M | 1,000 | $29.90 | $29,900 | 1,000 Direct | · | Acquired | -15.7% (price as of 2026-10-02) |
| June 3, 2014 | PCRX | A | 8,000 | · | · | 8,000 Direct | · | Acquired | (price as of 2026-10-02) |
| March 28, 2014 | PCRX | M | 1,000 | · | · | 6,000 Direct | -14.29% | Disposed | (price as of 2026-10-02) |
| March 28, 2014 | PCRX | S 10b5-1 | 1,000 | $64.63 | $64,630 | 0 Direct | -100.00% | Disposed | -61.0% (price as of 2026-10-02) |
| March 28, 2014 | PCRX | M | 1,000 | $29.90 | $29,900 | 1,000 Direct | · | Acquired | -15.7% (price as of 2026-10-02) |
| Dec. 30, 2013 | PCRX | M | 574 | · | · | 6,864 Direct | -7.72% | Disposed | (price as of 2026-10-02) |
| Dec. 30, 2013 | PCRX | M | 1,345 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| Dec. 30, 2013 | PCRX | M | 581 | · | · | 872 Direct | -39.99% | Disposed | (price as of 2026-10-02) |
| Dec. 30, 2013 | PCRX | S 10b5-1 | 2,500 | $55.55 | $138,875 | 0 Direct | -100.00% | Disposed | -54.6% (price as of 2026-10-02) |
| Dec. 30, 2013 | PCRX | M | 574 | $1.61 | $924 | 2,500 Direct | +29.80% | Acquired | 1465.8% (price as of 2026-10-02) |
| Dec. 30, 2013 | PCRX | M | 1,345 | $1.61 | $2,165 | 1,926 Direct | +231.50% | Acquired | 1465.8% (price as of 2026-10-02) |
| Dec. 30, 2013 | PCRX | M | 581 | $1.61 | $935 | 581 Direct | · | Acquired | 1465.8% (price as of 2026-10-02) |
| Sept. 30, 2013 | PCRX | M | 2,500 | · | · | 1,345 Direct | -65.02% | Disposed | (price as of 2026-10-02) |
| Sept. 30, 2013 | PCRX | S 10b5-1 | 2,500 | $46.74 | $116,850 | 0 Direct | -100.00% | Disposed | -46.1% (price as of 2026-10-02) |
| Sept. 30, 2013 | PCRX | M | 2,500 | $1.61 | $4,025 | 2,500 Direct | · | Acquired | 1465.8% (price as of 2026-10-02) |
| June 28, 2013 | PCRX | M | 804 | · | · | 3,845 Direct | -17.29% | Disposed | (price as of 2026-10-02) |
| June 28, 2013 | PCRX | M | 1,196 | · | · | 1,453 Direct | -45.15% | Disposed | (price as of 2026-10-02) |
| June 28, 2013 | PCRX | S 10b5-1 | 2,000 | $28.09 | $56,180 | 0 Direct | -100.00% | Disposed | -10.3% (price as of 2026-10-02) |
| June 28, 2013 | PCRX | M | 804 | $1.61 | $1,294 | 2,000 Direct | +67.22% | Acquired | 1465.8% (price as of 2026-10-02) |
| June 28, 2013 | PCRX | M | 1,196 | $1.61 | $1,926 | 1,196 Direct | · | Acquired | 1465.8% (price as of 2026-10-02) |
| June 12, 2013 | PCRX | A | 7,000 | · | · | 7,000 Direct | · | Acquired | (price as of 2026-10-02) |
| March 28, 2013 | PCRX | M | 2,000 | · | · | 2,649 Direct | -43.02% | Disposed | (price as of 2026-10-02) |
| March 28, 2013 | PCRX | S 10b5-1 | 2,000 | $28.49 | $56,980 | 0 Direct | -100.00% | Disposed | -11.5% (price as of 2026-10-02) |
| March 28, 2013 | PCRX | M | 2,000 | $1.61 | $3,220 | 2,000 Direct | · | Acquired | 1465.8% (price as of 2026-10-02) |
| June 5, 2012 | PCRX | A | 7,000 | · | · | 7,000 Direct | · | Acquired | (price as of 2026-10-02) |
| June 2, 2011 | PCRX | A | 5,000 | · | · | 5,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 3, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $10.81 | June 4, 2022 | 7,000 | Disposed |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $60.96 | June 9, 2031 | 7,626 | Acquired |
| March 1, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $13.98 | June 2, 2021 | 5,000 | Disposed |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $47.65 | June 9, 2030 | 8,027 | Acquired |
| March 12, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $1.61 | Sept. 2, 2020 | 3,736 | Disposed |
| Dec. 2, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $1.61 | Sept. 2, 2020 | 3,128 | Disposed |
| Dec. 2, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $1.61 | Sept. 2, 2020 | 872 | Disposed |
| June 5, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $43.54 | June 5, 2029 | 8,437 | Acquired |
| June 13, 2018 | PCRX | Stock Option (Right to Buy) | Common Stock | $38.35 | June 13, 2028 | 4,693 | Acquired |
| May 15, 2018 | RNTX | Stock Option (right to buy) | Common Stock | $5.50 | May 14, 2028 | 30,000 | Acquired |
| June 14, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock | $44.20 | June 14, 2027 | 2,714 | Acquired |
| June 15, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock | $40.34 | June 15, 2026 | 2,975 | Acquired |
| June 3, 2015 | PCRX | Stock Option (Right to Buy) | Common Stock | $79.43 | June 3, 2025 | 4,000 | Acquired |
| March 12, 2015 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.90 | June 11, 2023 | 3,000 | Disposed |
| Dec. 29, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.90 | June 11, 2023 | 1,000 | Disposed |
| Sept. 29, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.90 | June 11, 2023 | 1,000 | Disposed |
| June 30, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.90 | June 11, 2023 | 1,000 | Disposed |
| June 3, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock | $81.00 | June 3, 2024 | 8,000 | Acquired |
| March 28, 2014 | PCRX | Stock Option (right to buy) | Common Stock | $29.90 | June 11, 2023 | 1,000 | Disposed |
| Dec. 30, 2013 | PCRX | Stock Option (right to buy) | Common Stock | $1.61 | Sept. 2, 2020 | 574 | Disposed |
| Dec. 30, 2013 | PCRX | Stock Option (right to buy) | Common Stock | $1.61 | Sept. 2, 2020 | 1,345 | Disposed |
| Dec. 30, 2013 | PCRX | Stock Option (right to buy) | Common Stock | $1.61 | Sept. 2, 2020 | 581 | Disposed |
| Sept. 30, 2013 | PCRX | Stock Option (right to buy) | Common Stock | $1.61 | Sept. 2, 2020 | 2,500 | Disposed |
| June 28, 2013 | PCRX | Stock Option (right to buy) | Common Stock | $1.61 | Sept. 2, 2020 | 804 | Disposed |
| June 28, 2013 | PCRX | Stock Option (right to buy) | Common Stock | $1.61 | Sept. 2, 2020 | 1,196 | Disposed |
| June 12, 2013 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.20 | June 11, 2023 | 7,000 | Acquired |
| March 28, 2013 | PCRX | Stock Option (right to buy) | Common Stock | $1.61 | Sept. 2, 2020 | 2,000 | Disposed |
| June 5, 2012 | PCRX | Common Stock | Common Stock | $10.81 | June 4, 2022 | 7,000 | Acquired |
| June 2, 2011 | PCRX | Stock option (right to buy) | Common Stock | $13.98 | June 2, 2021 | 5,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2018 | $197,992 | $128,508 | · | · | · | · | $36,036 | $527,536 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.